title: Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
abstract: The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.
authors.affiliation: Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Mansfield
authors.affiliation: Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: H
authors.initials: H
authors.lastname: Dong
mesh_terms: D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D014408:Biomarkers, Tumor; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D007150:Immunohistochemistry; D016219:Immunotherapy, Adoptive / Q000379:methods; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018579:Patient Selection; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000096:biosynthesis
chemical_list: D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; D061026:Programmed Cell Death 1 Receptor